NEW YORK, Feb. 23, 2016 /PRNewswire/ -- Smoking cessation or nicotine de-addiction can be achieved by various modes such as nicotine replacement products, e-cigarettes, anti-depressants and nicotine receptor agonists such as Zyban (bupropion), and Chantix/Champix (varenicline). Quitting smoking is also possible with or without assistance of healthcare professionals. The smoking cessation products market has been extensively analyzed on the basis of factors such as the products popularly used, success rate, and geographical reach.
The global smoking cessation and nicotine de-addiction market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments and sub-segments of the market. It also provides information and data analysis of the global smoking cessation and nicotine de-addiction market with respect to the segments based on the type of products, and their geographic analysis (by country). A detailed qualitative analysis of driving and restraining factors for the market growth and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis, and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global smoking cessation and nicotine de-addiction market.
Based on type of products, the smoking cessation and nicotine de-addiction market includes nicotine replacement therapy (NRT) products, drug therapy and e-cigarettes. The NRT products market is broadly segmented into nicotine containing gums, transdermal patches, lozenges, sublingual tablets, sprays and nasal inhalers. The prominently used brands for smoking cessation are Zyban and Chantix/Champix which comprise the drug therapy segment of the market. Geographically, the market is analyzed for four major regions, namely North America, Europe, Asia-Pacific and Rest of the World (RoW) The market segments have been extensively analyzed based on usefulness, efficacy, revenue, and geographical coverage. The market size and forecast in terms of USD million for each segment has been provided for the period from 2013 to 2023. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2015 to 2023, considering 2014 as the base year.
A competitive landscape, mapping all the market players and their respective shares in the smoking cessation and nicotine de-addiction products market for 2012 are provided in this report. Some of the major players profiled for NRT products include Johnson & Johnson, GSK, Pfizer, Takeda Pharmaceuticals Co. Ltd., Cipla, and Revolymer PLC. GSK and Pfizer lead the market for drug therapy while the key players profiled for e-cigarettes market include VMR products, and NJOY. Each of these smoking cessation and nicotine de-addiction products market players are profiled in the report considering parameters such as company overview, financial overview, business strategies, product portfolio and recent developments.
The global smoking cessation and nicotine de-addiction products market has been segmented as follows:
Global Smoking Cessation and Nicotine De-Addiction Products Market, by Type
Nicotine Replacement Therapy Products
Nicotine Transdermal Patches
Nicotine Subling ual Tablets
Global Smoking Cessation and Nicotine De-Addiction Products Market, by Geography
Rest of Europe
Rest of Asia Pacific
Rest of the World (RoW)
Latin America (LATAM)
Middle East and North Africa (MENA)
Read the full report: http://www.reportlinker.com/p03635647-summary/view-report.html
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: email@example.com
Intl: +1 339-368-6001